Genscript Probio News Today

R&D Innovation to Lead the Future, Deepening Customer Value Creation Sustained High Revenue Growth: GenScript Groups five-year CAGR stands at an impressive...

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco. The J.P. Morgan Healthcare Conference has...

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus to San Francisco.

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech,...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference in San...

Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly extends congratulations on this major milestone achievement. In this ABL103 program, GenScript ProBio provided the service of process development & optimization, clinical material manufacturing, and CTD documentation preparation for MFDS IND filing.

/PRNewswire/ -- The "Plasmid DNA Manufacturing Market by Scale of Operation, Application Area, Therapeutic Area, and Geography: Industry Trends and Global...

Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The

The Hybridoma Development Services research report provides a comprehensive analysis of the market size, share, overview and growth prospects influenc

Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2023" report has been added to ...